TP53TG1/STAT axis is involved in the development of colon cancer through affecting PD-L1 expression and immune escape mechanism of tumor cells

被引:0
|
作者
Ji, Wenmin [1 ,3 ]
Wang, Wenyan [2 ]
Wei, Yanfang [1 ]
机构
[1] Shanxi Med Univ, Hosp 1, Taiyuan 030001, Shanxi, Peoples R China
[2] Shanxi Inst Food & Drug Control, Taiyuan 030001, Shanxi, Peoples R China
[3] Shanxi Med Univ, Hosp 1, 85 Jiefang South Rd, Taiyuan 030000, Shanxi, Peoples R China
来源
AMERICAN JOURNAL OF CANCER RESEARCH | 2023年 / 13卷 / 11期
关键词
PD-1/PD-L1; TP53TG1; immune escape; STAT pathway; colon cancer; REGULATORY T-CELLS; LONG NONCODING RNA; CD8(+) T; IMMUNOTHERAPY; COMBINATION; THERAPY; TARGET; RESISTANCE; PROGNOSIS; CD4(+);
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This research is dedicated to investigating the mechanism of programmed cell death ligand 1 (PD-L1) and tumor protein 53 target gene 1 (TP53TG1) in immune regulation of colon cancer (CC). Expressions of TP53TG1, PDL1 and signal transducers and activators of transcription (STATs) in CC and their correlation were detected through bioinformatics analysis. Effects of PD-L1 and TP53TG1 on the CC were assessed by in vivo and in vitro experiments. Herein, PD-L1 level was negatively correlated with TP53TG1 expression, but was positively correlated with the levels of STATs. Both overexpressed TP53TG1 and PD-L1 antibody reversed the effects of CT26 cells on inhibiting cell proliferation, cytokine secretion and PD-L1 level, and enhancing the cytotoxicity of NK cells and CD8+ T cells. TP53TG1 reduced PD-L1 level by inactivating STATs pathway. Downregulation of PD-L1 increased cytokine secretion and T lymphocyte killing ability, promoted tumor cell apoptosis, and inhibited the tumor growth. Altogether, TP53TG1/STAT axis regulates the immunomodulatory mechanism of CC by reducing PD-L1 expression.
引用
收藏
页码:5218 / +
页数:19
相关论文
共 50 条
  • [41] Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis
    Yusheng Huang
    Lei Xia
    Xiangwu Tan
    Jingyi Zhang
    Weiwei Zeng
    Benxu Tan
    Xian Yu
    Wei Fang
    Zhenzhou Yang
    Cellular & Molecular Biology Letters, 2022, 27
  • [42] A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer
    Francisco Flores-Martin, Jose
    Perea, Francisco
    Exposito-Ruiz, Manuela
    Javier Carretero, Francisco
    Rodriguez, Teresa
    Villamediana, Marina
    Ruiz-Cabello, Francisco
    Garrido, Federico
    Manuel Cozar-Olmo, Jose
    Aptsiauri, Natalia
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (08) : 2631 - 2639
  • [43] A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape
    Sabarwal, Akash
    Chakraborty, Samik
    Mahanta, Simran
    Banerjee, Selina
    Balan, Murugabaskar
    Pal, Soumitro
    CANCERS, 2020, 12 (07) : 1 - 17
  • [44] Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer
    Birtalan, Ede
    Danos, Kornel
    Gurbi, Bianka
    Brauswetter, Diana
    Halasz, Judit
    Piurko, Violetta Kalocsane
    Antal, Biborka
    Mihalyi, Reka
    Pato, Anna
    Fent, Zoltan
    Polony, Gabor
    Timar, Jozsef
    Tamas, Laszlo
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2018, 26 (07) : E79 - E85
  • [45] Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells
    Tawfik, Ossama
    Kimler, Bruce F.
    Karnik, Tejashree
    Shehata, Peter
    HUMAN PATHOLOGY, 2018, 80 : 170 - 178
  • [46] Upregulated LINC01088 facilitates malignant phenotypes and immune escape of colorectal cancer by regulating microRNAs/G3BP1/PD-L1 axis
    Li, Chenmeng
    Pan, Bei
    Wang, Xuhong
    Liu, Xiangxiang
    Qin, Jian
    Gao, Tianyi
    Sun, Huiling
    Pan, Yuqin
    Wang, Shukui
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (08) : 1965 - 1982
  • [47] Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors
    Takamori, Shinkichi
    Takada, Kazuki
    Tagawa, Tetsuzo
    Toyokawa, Gouji
    Hirai, Fumihiko
    Yamashita, Nami
    Okamoto, Tatsuro
    Oki, Eiji
    Yoshizumi, Tomoharu
    Od, Yoshinao
    Maehara, Yoshihiko
    SURGICAL ONCOLOGY-OXFORD, 2018, 27 (04): : 637 - 641
  • [48] Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
    He, Jiabei
    Hu, Ying
    Hu, Mingming
    Li, Baolan
    SCIENTIFIC REPORTS, 2015, 5
  • [49] Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature
    Bao, Rui
    Wang, Yanpu
    Lai, Jianhao
    Zhu, Hua
    Zhao, Yang
    Li, Suping
    Li, Nan
    Huang, Jing
    Yang, Zhi
    Wang, Fan
    Liu, Zhaofei
    MOLECULAR PHARMACEUTICS, 2019, 16 (01) : 339 - 348
  • [50] Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
    Antonios, Joseph P.
    Soto, Horacio
    Everson, Richard G.
    Moughon, Diana
    Orpilla, Joey R.
    Shin, Namjo P.
    Sedighim, Shaina
    Treger, Janet
    Odesa, Sylvia
    Tucker, Alexander
    Yong, William H.
    Li, Gang
    Cloughesy, Timothy F.
    Liau, Linda M.
    Prins, Robert M.
    NEURO-ONCOLOGY, 2017, 19 (06) : 796 - 807